Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Abivax SA
PAR:ABVX
|
FR |
|
Oma Saastopankki Oyj
F:OM0
|
FI |
|
S
|
Standard Chartered PLC
F:STD
|
UK |
|
A
|
Aditya Infotech Ltd
NSE:CPPLUS
|
IN |
|
A
|
Alkane Resources Ltd
XMUN:AK7
|
AU |
|
edding AG
F:EDD3
|
DE |
|
S
|
Sdi Group PLC
F:SD0
|
UK |
|
I
|
Industrial and Commercial Bank of China Ltd
DUS:ICK
|
CN |
|
W
|
West Fraser Timber Co Ltd
F:WFC
|
CA |
|
Focus Minerals Ltd
ASX:FML
|
AU |
|
N
|
NetApp Inc
XMUN:NTA
|
US |
|
Suedwestdeutsche Salzwerke AG
F:SSH
|
DE |
Intrinsic Value
Is ABVX undervalued or overvalued?
See the intrinsic value estimate for Abivax SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ABVX looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with ABVX’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Abivax Does
Abivax is a biotechnology company that develops drug candidates for inflammatory and immune-driven diseases. Its main work is research and clinical testing, especially for conditions like ulcerative colitis, where it is trying to turn its lead molecule into a prescription medicine. It is not a broad drug seller; it is a drug developer that owns and advances its own clinical programs.
- Headquarters
- France FR
- Employees
- 80
- IPO date
- Jun 26, 2015
Earnings Waterfall
Abivax SA
The intrinsic value for Abivax SA (ABVX) under the Base Case is hidden EUR.
Compared with the current market price of 78.15 EUR, the stock appears hidden.